1. Name Of The Medicinal Product
Imuvac sub-unit 2011/2012, suspension for injection (influenza vaccine, surface antigen, inactivated).
2. Qualitative And Quantitative Composition
Influenza virus surface antigens (inactivated) (haemagglutinin and neuraminidase) of the following strains*:
|
|
|
|
|
|
|
* propagated in fertilised hens' eggs from healthy chicken flocks.
** haemagglutinin.
This vaccine complies with the WHO recommendation (northern hemisphere), and EU decision for the 2011/2012 season.
For a full list of excipients see section 6.1.
3. Pharmaceutical Form
Suspension for injection in prefilled syringes; a colourless clear liquid, filled in single-dose syringes (glass, type I).
4. Clinical Particulars
4.1 Therapeutic Indications
Prophylaxis of influenza, especially in those who run an increased risk of associated complications.
The use of Imuvac should be based on official recommendations.
4.2 Posology And Method Of Administration
Adults and children from 36 months: 0.5 ml.
Children from 6 months to 35 months: Clinical data are limited. Dosages of 0.25 ml or 0.5 ml have been used.
For children who have not previously been vaccinated, a second dose should be given after an interval of at least 4 weeks.
Immunisation should be carried out by intramuscular or deep subcutaneous injection.
For instructions for preparation, see section 6.6.
4.3 Contraindications
Hypersensitivity to the active substances, to any of the excipients and to residues of eggs, chicken proteins (such as ovalbumin), formaldehyde, cetyltrimethylammonium bromide, polysorbate 80, or gentamicin.
Immunisation should be postponed in patients with febrile illness or acute infection.
4.4 Special Warnings And Precautions For Use
As with all injectable vaccines, appropriate medical treatment and supervision should always be readily available in case of an anaphylactic event following the administration of the vaccine.
Imuvac should under no circumstances be administered intravascularly.
Antibody response in patients with endogenous or iatrogenic immunosuppression may be insufficient.
4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction
Imuvac may be given at the same time as other vaccines. Immunisation should be carried out on separate limbs. It should be noted that the adverse reactions may be intensified.
The immunological response may be diminished if the patient is undergoing immunosuppressant treatment.
Following influenza vaccination, false positive results in serology tests using the ELISA method to detect antibodies against HIV1, Hepatitis C and especially HTLV1 have been observed. The Western Blot technique disproves the false-positive ELISA test results. The transient false-positive reactions could be due to the IgM response by the vaccine.
4.6 Pregnancy And Lactation
The limited data from vaccinations in pregnant women do not indicate that adverse fetal and maternal outcomes were attributable to the vaccine. The use of this vaccine may be considered from the second trimester of pregnancy. For pregnant women with medical conditions that increase their risk of complications from influenza, administration of the vaccine is recommended, irrespective of their stage of pregnancy.
Imuvac may be used during lactation.
4.7 Effects On Ability To Drive And Use Machines
Imuvac is unlikely to produce an effect on the ability to drive and use machines.
4.8 Undesirable Effects
ADVERSE REACTIONS OBSERVED FROM CLINICAL TRIALS
The safety of trivalent inactivated influenza vaccines is assessed in open label, uncontrolled clinical trials performed as annual update requirement, including at least 50 adults aged 18 - 60 years of age and at least 50 elderly aged 61 years or older. Safety evaluation is performed during the first 3 days following vaccination.
The following undesirable effects have been observed during clinical trials with the following frequencies:
very common (
|
|
|
|
|
|
|
| ||||
|
| ||||
|
| ||||
|
|
* These reactions usually disappear within 1-2 days without treatment
ADVERSE REACTIONS REPORTED FROM POST-MARKETING SURVEILLANCE
Adverse reactions reported from post marketing surveillance are, in addition to the reactions which have also been observed during the clinical trials, the following:
Blood and lymphatic system disorders:
Transient thrombocytopenia, transient lymphadenopathy
Immune system disorders:
Allergic reactions, in rare cases leading to shock, angioedema
Nervous system disorders:
Neuralgia, paraesthesia, febrile convulsions, neurological disorders, such as encephalomyelitis, neuritis and Guillain Barré syndrome
Vascular disorders:
Vasculitis associated in very rare cases with transient renal involvement
Skin and subcutaneous tissue disorders:
Generalised skin reactions including pruritus, urticaria or non-specific rash
4.9 Overdose
Overdosage is unlikely to have any untoward effect.
5. Pharmacological Properties
5.1 Pharmacodynamic Properties
Pharmacotherapeutic group: Influenza vaccine, ATC Code: J07BB02.
Seroprotection is generally obtained within 2 to 3 weeks. The duration of post-vaccinal immunity to homologous strains or to strains closely related to the vaccine strains varies but is usually 6-12 months.
5.2 Pharmacokinetic Properties
Not applicable.
5.3 Preclinical Safety Data
Not applicable.
6. Pharmaceutical Particulars
6.1 List Of Excipients
Potassium chloride, potassium dihydrogen phosphate, disodium phosphate dihydrate, sodium chloride, calcium chloride dihydrate, magnesium chloride hexahydrate and water for injections.
6.2 Incompatibilities
In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.
6.3 Shelf Life
1 year.
6.4 Special Precautions For Storage
Imuvac should be stored in a refrigerator (+2°C to +8°C).
Do not freeze.
Protect from light.
6.5 Nature And Contents Of Container
0.5 ml suspension for injection in prefilled syringe with/without needle (glass, type I), pack of 1 or 10.
6.6 Special Precautions For Disposal And Other Handling
Imuvac should be allowed to reach room temperature before use.
Shake before use.
For administration of a 0.25 ml dose from a syringe, push the front side of the plunger exactly to the edge of the hub (the knurled polypropylene ring); a reproducible volume of vaccine remains in the syringe, suitable for administration. See also section 4.2.
Any unused product or waste material should be disposed of in accordance with local requirements.
7. Marketing Authorisation Holder
Abbott Healthcare Products Limited
Mansbridge Road
West End
Southampton
SO18 3JD
8. Marketing Authorisation Number(S)
PL 00512/0188
9. Date Of First Authorisation/Renewal Of The Authorisation
31 March 2005 / 23 September 2009
10. Date Of Revision Of The Text
12 /04/ 2011
No comments:
Post a Comment